![New study finds higher rates of newly diagnosed type 2 diabetes after infection with mild COVID-19 – Diabetologia New study finds higher rates of newly diagnosed type 2 diabetes after infection with mild COVID-19 – Diabetologia](https://diabetologia-journal.org/wp-content/uploads/2022/03/Screenshot-2022-03-15-at-13.18.58.png)
New study finds higher rates of newly diagnosed type 2 diabetes after infection with mild COVID-19 – Diabetologia
![Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial - The Lancet Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial - The Lancet](https://www.thelancet.com/cms/asset/ec7971ea-a30f-42fe-8306-9cbdb0c51b86/gr1.jpg)
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial - The Lancet
![Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial - The Lancet Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial - The Lancet](https://www.thelancet.com/cms/attachment/3accb9b7-fb14-48da-9310-396282245ca8/gr1_lrg.gif)
Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial - The Lancet
![Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial - The Lancet Diabetes & Endocrinology Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/f4ba0249-c2a1-4a1c-8e39-542307cf1b14/gr1.gif)
Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial - The Lancet Diabetes & Endocrinology
![The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes | SpringerLink The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-020-05303-4/MediaObjects/125_2020_5303_Figa_HTML.png)
The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes | SpringerLink
![The medications and health care utilization of patients newly diagnosed with type 2 diabetes mellitus: A nationwide population-based cohort study - ScienceDirect The medications and health care utilization of patients newly diagnosed with type 2 diabetes mellitus: A nationwide population-based cohort study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0929664620300747-gr1.jpg)
The medications and health care utilization of patients newly diagnosed with type 2 diabetes mellitus: A nationwide population-based cohort study - ScienceDirect
![The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes – published online 19/10/2020 – Diabetologia The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes – published online 19/10/2020 – Diabetologia](https://diabetologia-journal.org/wp-content/uploads/2021/01/rohde-tweet.jpg)
The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA1c/LDL target achievement in newly diagnosed type 2 diabetes – published online 19/10/2020 – Diabetologia
Prevalence of microvascular and macrovascular complications of diabetes in newly diagnosed type 2 diabetes in low-and-middle-income countries: A systematic review and meta-analysis | PLOS Global Public Health
![Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial - The Lancet Diabetes & Endocrinology Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/dbc74651-c151-41ff-8566-4d9625cc14b9/gr1.gif)